A study from Korea showed that the positive rate of autoantibody against Prdx1 was 47.0% in 53 sera from NSCLC patients by western blot analysis, whereas it was only 8.0% for the anti-Prdx1 antibody in 50 normal individual controls (11). This evidence concerns the gene PRDX1 and non-small cell lung carcinoma.